Recruiting
Phase 2

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor:

University of Washington

Code:

NCT04387227

Conditions

Recurrent Fallopian Tube Carcinoma

Recurrent Ovarian Carcinoma

Recurrent Primary Peritoneal Carcinoma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Pembrolizumab

Computed Tomography

Magnetic Resonance Imaging

Biospecimen Collection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information